Equities

GVS SpA

GVS SpA

Actions
IndustrialsGeneral Industrials
  • Price (EUR)6.58
  • Today's Change0.21 / 3.30%
  • Shares traded90.17k
  • 1 Year change+18.56%
  • Beta0.4650
Data delayed at least 15 minutes, as of Jul 03 2024 16:35 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

GVS SpA is an Italy-based manufacturer of filters and components for applications in the healthcare, life sciences, automotive, appliance, safety, commercial and industrial filtration. Its offering includes seven product lines: Healthcare, Laboratory, Mobility, Air Safety, Appliance, Personal Safety and Membranes. Each product line provides a suite of customizable solutions specifically related to each market. Additionally, the Company offers tailormade product and process development services, which cover all the project stages, including product and process design, validation, up to the mass production for large quantities. It is active globally.

  • Revenue in EUR (TTM)424.67m
  • Net income in EUR20.54m
  • Incorporated1992
  • Employees4.39k
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
medmix AG500.98m308.87k591.35m2.66k1,389.221.2210.261.180.010.0111.9111.410.46063.656.05183,070.000.06632.060.08462.4932.4136.380.14394.161.232.920.424467.701.991.40-97.41-64.3612.01--
Paul Hartmann AG2.35bn28.42m718.06m10.17k25.120.67135.290.30518.008.00662.57299.401.182.025.72231,438.001.643.872.265.3456.0156.711.392.981.164.870.186542.751.802.12-21.37-18.495.952.71
Revenio Group Oyj96.68m19.01m727.86m216.0037.867.2631.717.530.72050.72053.663.760.70695.507.60447,574.1013.9014.3316.7717.9051.0150.7319.6621.131.7928.490.152155.81-0.412525.80-12.1518.7217.676.30
El En SpA692.29m48.24m752.69m2.11k15.572.1712.161.090.60380.60388.674.330.95152.044.05332,511.906.887.4312.8313.5239.1438.837.237.631.20232.140.164--2.7814.88-12.4723.49-13.40--
ChemoMetec A/S53.83m19.28m809.11m171.0041.9812.1037.2115.038.268.2623.0728.660.69820.80646.012,448,421.0025.0030.4329.6938.9978.8579.4435.8134.173.37--0.011846.903.7431.5812.0457.8819.91--
Draegerwerk AG & Co KGaA3.35bn100.48m863.24m16.48k8.160.57243.430.25785.365.36178.4876.351.112.614.94205,046.003.393.265.034.8743.3244.163.063.051.175.790.166211.3810.785.39271.0533.872.6455.73
Arjo AB (publ)976.47m45.56m910.33m6.71k21.411.376.680.93231.901.9040.7629.720.69114.156.311,632,980.003.213.554.445.5543.4344.014.645.410.69134.140.402443.0110.035.976.9010.15-8.8910.35
Medartis Holding AG218.27m637.30k964.76m829.001,413.933.3443.354.420.04880.048817.3320.630.62590.6435.27255,737.000.1830.19190.20950.215379.0482.330.29240.35421.591.460.16550.0015.9611.81110.70-31.825.37--
Oxford Nanopore Technologies PLC200.30m-182.40m1.02bn1.24k--1.33--5.11-0.1851-0.18510.20350.74930.2120.83692.73137,050.10-19.30-21.12-21.93-24.6753.3353.90-91.06-81.853.87--0.0608---14.5739.15-69.74--8.92--
GVS SpA424.67m20.54m1.11bn4.39k56.113.2117.042.630.11350.11352.381.990.42011.956.2096,823.302.037.352.5010.8253.9258.744.8412.441.193.870.5709--9.5815.25-43.37-9.9716.08--
Biotage AB174.25m20.76m1.13bn669.0053.183.2931.786.473.013.0125.5748.610.52762.017.782,939,169.006.2910.747.3312.7762.1961.3411.9115.771.528.950.06240.1118.9015.37-8.217.9714.051.30
Xvivo Perfusion AB56.56m8.83m1.13bn148.00123.006.4277.9619.993.323.3221.1863.590.3221.284.274,018,431.005.031.245.491.3373.9473.1415.624.763.40--0.01520.0043.8826.04398.2948.5721.35--
Data as of Jul 03 2024. Currency figures normalised to GVS SpA's reporting currency: Euro EUR

Institutional shareholders

16.79%Per cent of shares held by top holders
HolderShares% Held
Capital Research & Management Co. (World Investors)as of 31 Mar 20248.72m4.98%
Mediolanum Gestione Fondi SGRpAas of 29 Dec 20234.19m2.40%
Invesco Asset Management Ltd.as of 29 Feb 20243.13m1.79%
T. Rowe Price International Ltd.as of 31 Mar 20242.76m1.58%
The Vanguard Group, Inc.as of 06 Jun 20242.45m1.40%
Amundi Asset Management SA (Investment Management)as of 05 Jun 20241.81m1.04%
Joh. Berenberg, Gossler & Co. KG (Investment Management)as of 31 May 20231.74m0.99%
Fideuram Asset Management SGR SpAas of 31 May 20241.73m0.99%
Fidelity Management & Research Co. LLCas of 30 Apr 20241.55m0.89%
Oddo BHF Asset Management SASas of 31 May 20241.30m0.74%
More ▼
Data from 28 Mar 2024 - 26 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.